Bisphosphonates/denosumab

  • PDF / 169,775 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 108 Downloads / 172 Views

DOWNLOAD

REPORT

1 S

Mandibular osteonecrosis of jaw: 21 case reports In an observational study (patients enrolled between April 2017 and December 2018), 21 patients (15 women and 6 men) aged 55–87 years were described, who developed mandibular anti-resorptive agent-related osteonecrosis of jaw (ARONJ) while receiving anti-resorptive therapy with zoledronic acid, denosumab, minodronic acid, alendronic acid, risedronic acid or ibandronic acid for prostate cancer, osteoporosis, lung cancer, multiple myeloma or breast cancer [routes, dosages, durations of treatments to reactions onsets and outcomes not stated]. The patients had prostate cancer (4 patients), primary osteoporosis (3 patients), lung cancer (3 patients), osteoporosis due to unspecified glucocorticoids (4 patients), multiple myeloma (1 patient) and breast cancer (6 patients). Therefore, the patients had been receiving zoledronic acid [zoledronate; 9 patients], denosumab (7 patients), alendronic acid [alendronate; 3 patients] and minodronic acid [minodronate; 2 patients]. In seven of these 21 patients, the therapy was changed to denosumab (5 patients) and risedronic acid (2 patients). Of these seven patients, two patients’ therapy was further switched to minodronic acid (1 patient) and ibandronic acid (1 patient). During the course of anti-resorptive treatment, the patients developed mandibular ARONJ. On the basis of single photon emission computed tomography, ARONJ staging was stage 1–3. Okui T, et al. Quantitative evaluation of anti-resorptive agent-related osteonecrosis of the jaw using bone single photon emission computed tomography in clinical settings: relationship between clinical stage and imaging. Annals of Nuclear Medicine 34: 620-628, No. 9, Sep 2020. Available from: URL: http://doi.org/10.1007/ 803502210 s12149-020-01485-4

0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 19 Sep 2020 No. 1822

Data Loading...